Efficacy and Safety of Sunitinib as Long-term Treatment in Japanese Patients with Advanced Pancreatic Neuroendocrine Tumors.

#1264

Introduction: The results from recent clinical trials have suggested the ethnical difference in antitumor activity of sunitinib against advanced pancreatic neuroendocrine tumors (PNET), which seemed to be higher in Japanese than those in Western patients.

Aim(s): To evaluate the efficacy and safety of sunitinib in Japanese patients with advanced PNET.

Materials and methods: A total of 15 patients with advanced PNET (median age 57 years, 40% male, 33% NETG1) treated with sunitinib in our hospital were retrospectively reviewed. The primary endpoint was clinical benefit rate (CBR). The secondary endpoints included objective response rate (ORR), progression-free survival (PFS) probability and safety.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Lee L

Authors: Lee L, Ueda K, Fujiyama T, Tachibana Y, Yasunaga K,

Keywords: sunitinib, pancreatic neuroendocrine tumor,